GENF vs. IMM, ROQ, BSFA, BVX, VAL, IXI, OCTP, EVG, APTA, and FAB
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include ImmuPharma (IMM), Roquefort Therapeutics (ROQ), BSF Enterprise (BSFA), BiVictriX Therapeutics (BVX), ValiRx (VAL), IXICO (IXI), Oxford Cannabinoid Technologies (OCTP), Evgen Pharma (EVG), Aptamer Group (APTA), and Fusion Antibodies (FAB). These companies are all part of the "biotechnology" industry.
Genflow Biosciences (LON:GENF) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
In the previous week, ImmuPharma had 2 more articles in the media than Genflow Biosciences. MarketBeat recorded 2 mentions for ImmuPharma and 0 mentions for Genflow Biosciences. Genflow Biosciences' average media sentiment score of 1.38 beat ImmuPharma's score of 0.68 indicating that Genflow Biosciences is being referred to more favorably in the media.
9.2% of Genflow Biosciences shares are held by institutional investors. Comparatively, 21.1% of ImmuPharma shares are held by institutional investors. 63.7% of Genflow Biosciences shares are held by company insiders. Comparatively, 43.0% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Genflow Biosciences' return on equity of -51.61% beat ImmuPharma's return on equity.
ImmuPharma received 266 more outperform votes than Genflow Biosciences when rated by MarketBeat users.
Genflow Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Genflow Biosciences has higher earnings, but lower revenue than ImmuPharma.
Summary
Genflow Biosciences beats ImmuPharma on 6 of the 11 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
